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Abstract
Effects of the direct NMDA agonist (tetrazol-5-yl)glycine (TZG) were examined in a genetic mouse
model of reduced NMDA receptor function. In this model, expression of the NR1 subunit is reduced
but not eliminated and the mice are therefore designated as NR1 hypomorphic. Previous work
suggested that the reduced NR1 subunit expression produced a functional subsensitivity as judged
by a blunted Fos induction response to a sub-seizure dose of TZG. In the present study seizure
threshold doses of TZG were tested in the wild type and mutant mice. Surprisingly, there was no
difference in the seizure sensitivity between the wild type mice and mice presumed to express very
low levels of the NR1 subunit. An extensive neuroanatomical analysis of Fos induction was
conducted after the threshold seizure doses of TZG. The results demonstrate that some brain regions
of the NR1 -/- mice exhibit much lower Fos induction in comparison to the NR1 +/+ mice. These
regions include hippocampus, amygdala, and cerebral cortical regions. However, in other regions,
similar induction of Fos was observed in both genotypes in response to the NMDA agonist. Regions
showing similar Fos induction in the NR1 +/+ and NR1 -/- mice include the lateral septum, nucleus
of the solitary tract, and medial hypothalamic regions. The results suggest that the NMDA receptor
hypofunction in the NR1 -/- mice is not global but regionally specific and that subcortical structures
are responsible for the seizure-inducing effects of TZG.
Section 3—Neurophysiology, Neuropharmacology and other forms of Intercellular
Communication
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1. Introduction
The psychotomimetic actions of NMDA antagonists suggest that endogenously reduced
NMDA hypofunction could contribute to the pathophysiology of schizophrenia (Javitt and
Zukin, 1991; Krystal et al., 1994; Lahti et al., 1995; Olney and Farber, 1995; Vollenweider et
al., 1997; Lahti et al., 2001). A mouse line expressing low levels of the NR1 subunit of the
NMDA receptor has been developed that provides a model of endogenous NMDA receptor
hypofunction (Mohn et al., 1999). This mutant line was created by insertion of a neomyosin
resistance gene into an intron of the NR1 locus, which results in marked under-expression of
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the gene. The mice are referred to as NR1 hypomorphic since expression of the gene is reduced
but not eliminated. Estimates of the magnitude of the reduced NR1 expression vary between
90%-70% depending on the assessment method and brain region examined (Mohn et al.,
1999; Duncan et al., 2002).
The NR hypomorphic mice (NR1 -/-) exhibit a number of phenotypes that support their utility
to model certain characteristics of schizophrenia patients. These altered phenotypes include
reduced locomotor habituation (Mohn et al., 1999), reduced metabolic activity in the anterior
cingulate cortex and the hippocampus (Duncan et al., 2002), deficits in social interactions
(Mohn et al., 1999; Duncan et al., 2004), and deficits in prepulse inhibition of acoustic startle
(PPI) (Duncan et al., 2004; Fradley et al., 2005; Duncan et al., 2006). In addition, the NR1 -/-
mice show enhanced sensitivity to amphetamine-induced PPI disruption (Moy et al., 2006) but
not to the locomotor stimulatory effects of amphetamine (Miyamoto et al., 2004).
Previous work indicated that the reduced expression of the NR1 subunit in the NR1 -/- mice
is associated with reduced functional activation of the NMDA receptor (Inada et al., 2007). In
wild type mice, a sub-seizure dose of the direct NMDA agonist (tetrazol-5-yl)glycine (TZG)
induced Fos protein in a limited and neuroanatomically selective manner (Inada et al., 2007).
TZG is a highly selective and potent direct NMDA agonist that readily penetrates the blood
brain barrier(Schoepp et al., 1991). The most robust induction of the protein after TZG was
found in the hippocampal cellular layers (CA1-CA4) and in the granule cell layer of the dentate
gyrus. In the NR1 -/- mice, TZG-induced Fos was greatly attenuated in all regions examined
(Inada et al., 2007).
The 0.75 mg/kg dose of TZG tested in NR1 -/- and NR1 +/+ mice in the previous study (Inada
et al., 2007) did not induce any behavioral signs of seizure activity in either genotype. However,
TZG can induce tonic-clonic seizures and exhibits a very steep dose response for seizure
induction (Schoepp et al., 1991; Lunn et al., 1992). Consitent with the study of Inada et al.
(2007), Schoepp et al. (1991) found that a TZG dose of 0.75 mg/kg did not induce seizures in
any mice tested. However, at 1.25 mg/kg, TZG induced tonic-clonic convulsions in
approximately 30% of mice and at 2.5 mg/kg seizures were induced in 100% of the animals
(Schoepp et al., 1991). TZG-induced tonic-clonic seizures were lethal in all mice. In the present
study, TZG was given in threshold seizure doses of 1.25 and 1.5 mg/kg to wild type and NR1
deficient mice to determine if the mutant mice would exhibit altered seizure sensitivity to this
direct NMDA receptor agonist.
2. Results
2.1 Behavior
An initial experiment tested TZG at 1.5 mg/kg in 5 NR1 +/+ and 5 NR1 -/- mice. For both
genotypes, 3/5 mice in each group exhibited tonic clonic seizures 10-15 minutes after injection
of 1.5 mg/kg TZG (Table 1). The seizures were lethal in all cases. The mice that did not show
tonic-clonic convulsive activity at the 1.5 mg/kg dose of TZG displayed some locomotor
hyperactivity but no obvious seizure activity.
For the 1.25 mg/kg dose of TZG, 3/19 of the NR1 +/+ mice and 5/14 of the NR1 -/- mice
exhibited lethal tonic-clonic seizures within 15 minutes after injection (Table 1). For mice that
did not exhibit tonic-clonic seizures at the 1.25 mg/kg TZG dose, there was considerable
variability of behavioral responses for both NR1 +/+ and NR1 -/- genotypes. Some mice
showed no obvious behavioral effects and others showed modest locomotor hyperactivity.
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A two-by-two logistic regression for the TZG treated mice showed a significant dose effect (P
< .05) indicating that the two doses produced different proportions of seizures. There was no
significant effect of genotype (P<0.48) and a non-significant interaction effect (P<0.48).
2.2 Induction of Fos Protein
TZG induced robust induction of Fos in select brain regions. In some regions the Fos response
was markedly blunted in the NR1 -/- mice (Figure 1 A). However, in other regions the induction
of Fos in the mutant mice in response to TZG was comparable to the wild type controls (Figure
1 B). Photomicrographs of sections immunocytochemically stained for Fos are shown in
Figures 2-5 and demonstrate the striking differences and similarities in Fos staining in specific
regions between the NR1 +/+ and NR1-/- mice.
In NR1 +/+ mice robust induction of Fos by TZG was found in the hippocampal formation,
hypothalamus, lateral septum, nucleus accumbens, and nucleus of the solitary tract. Within the
hypothalamus the response was regionally selective with the most intense staining seen in the
dorsal medial, ventromedial nuclei and arcuate nucleus.
In the NR1 -/- mice, induction of Fos was markedly attenuated in comparison to the NR1 +/+
in the hippocampal formation, cerebral cortical regions, and amygdala after administration
TZG (Figure 1 A). However, for the NR -/- mice, as observed for the NR1 +/+ mice, robust
induction of Fos was found in the lateral septal nucleus, sub-regions of the hypothalamus, bed
nucleus of the stria terminalis, nucleus accumbens, and nucleus of the solitary tract (Figure 1
B).
3. Discussion
The NR1 hypomorphic mice developed by Mohn et al. (1999) provide a valuable model to
study endogenous NMDA receptor hypofunction. Autoradiographic assessment of
regional 3H-MK-801 binding in the mutant mice suggested a global reduction in ligand binding
with 85% reductions found in the hippocampus and approximately 70% reductions in other
brain regions examined (Duncan et al., 2002). Previous work indicated that the reduced NR1
subunit expression was accompanied by reduced functional sensitivity of the NMDA receptor,
as judged by a markedly blunted response to a sub-seizure dose of TZG (0.75 mg/kg) (Inada
et al., 2007).
In the present study there was surprisingly no reduction in seizure responses to threshold seizure
doses of TZG in the NR1 -/- mice compared to wild type controls. With regard to Fos, induction
of the protein by the threshold seizure doses of TZG was markedly reduced in the hippocampus,
amygdala, and cerebral cortex in the NR1 -/- mice. However, many subcortical structures
showed equivalent expression of TZG-induced Fos in the mutant and control mice. These data
indicate that the NMDA receptor hypofunction in the NR1 -/- mice is not global but regionally
specific and suggest that subcortical structures are responsible for seizures induced by the
NMDA agonist.
It was not possible to examine Fos expression in the mice that exhibited tonic-clonic
convulsions because those animals died within 15 min after injection of TZG. There was thus
insufficient time to allow synthesis of Fos protein in those animals. It is possible that additional
brain regions not identified in the Fos mapping studies were involved in mice that responded
to TZG with convulsive activity. However the specific neuroanatomical regions activated by
TZG at the threshold seizure doses suggest that those regions could be involved in the initiation
of the seizures.
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Previous work that studied effects of amphetamine on Fos induction in the NR1 -/- and NR1
+/+ mice showed similar activation in subcortical structures for both genotypes (Miyamoto et
al., 2004). For example, the caudate putamen and nucleus accumbens showed similar intense
Fos expression in the NR1 -/- and NR1 +/+ mice in response to amphetamine. In contrast, in
cerebral cortical regions exhibited greatly reduced Fos responses after amphetamine
administration in the NR1 -/- mice in comparison to controls. Since NMDA receptor activation
has been implicated in the Fos response to amphetamine in the striatum (Snyderkeller, 1991;
Ohno et al., 1994; Konradi et al., 1996), the findings of Miyamoto et al.(Miyamoto et al.,
2004) are consistent with the interpretation of the present study that NMDA hypofunction in
the NR1 -/- mice is neuroanatomically selective.
The most prominently activated subcortical regions by TZG were medial hypothalamic
structures, nucleus of the solitary tract, and lateral septum. Induction of Fos by systemic
administration of NMDA in those brain regions has also been reported by other investigators
(Knapp et al., 2001; Velisek et al., 2007). Furthermore, induction of seizures with PTZ and
electroshock induces a massive Fos response in the VMH and nucleus of the solitary tract
(Kanter et al., 1996; Andre et al., 1998; Barton et al., 2001; Eells et al., 2004). Additional
support for a role of the VMH in seizures is that lesioning the region disrupts propagation of
seizure activity from the forebrain to the brain stem (Ferland and Applegate, 1998). Further
work is necessary to determine if seizures could be induced by direct application of NMDA
agonists to the hypothalamus or other structures activated by systemic administration of TZG.
Stimulation of the nucleus of the solitary tract via vagal nerve stimulation (VNS) has been
shown to suppress seizure activity in experimental animals and in humans (for reviews see
(Cohen-Gadol et al., 2003; Vonck et al., 2004). It is therefore curious that this region was
prominently activated by TZG in the present work and by NMDA in the study of Velisek et
al. (2007) in infant rats. The induction of Fos in the nucleus of the solitary tract in response to
NMDA agonists raises the possibility that the region could participate in the induction of tonic-
clonic seizures. Behavioral assessment after site injection of TZG into this brainstem nucleus
could test that possibility.
The neurobiological basis for therapeutic effects of VNS are unknown. Current hypotheses
propose that VNS activates neurons in the nucleus of the solitary tract that project to forebrain
structures to produce the therapeutic effects (Groves and Brown, 2005; Nemeroff et al.,
2006). However, if the NTS is directly involved in seizure induction by NMDA agonists (or
in epilepsy) an alternative mechanism could be disruption of seizure-related activity directly
in the region. NMDA receptor antagonists are highly effective in animal models of epilepsy
but are not used in humans because they induce psychotomimetic effects (Dingledine et al.,
1990; Klitgaard, 2005). If NMDA receptors in hypothalamic and brain stem regions are directly
involved in genesis of seizures, NMDA antagonists that selectively target such regions could
be effective antiepileptic agents with out producing psychotomimetic side effects that limit the
use of currently available drugs that block NMDA receptors.
4. Experimental Procedure
4.1 Animals
The NR1 deficient mice were generated by incorporating a neomysin resistance gene in to an
intron of the NR1 locus. The initial mutation was inserted in mice of a mixed genetic
background consisting of alleles derived from 129/SvEv, C57BL/6, and DBA/2 (Mohn et al.,
1999). This insertion mutation greatly reduces expression of the NR1 gene in all brain regions
thus far examined. Modifier alleles present in various inbred mouse lines can dramatically alter
the impact of primary genetic lesions. Therefore, to obtain populations of mice that differ
genetically only at the NR1 locus, a strategy was devised to generate NR1 hypomorphic mice
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and genetically identical wild type populations. C57BL/6 heterozygous animals were
intercrossed with 129-SvEv heterozygous animals. All of the F1 offspring of these litters are
genetically identical at all loci except at the NR1 gene. The 129-SvEv mice were used as moms
and were co-isogenic. C57BL/6 mice were backcrossed > 14 generations from C57BL/6 mice
purchased from Jackson Laboratories. Analysis of the F1 hybrid litters showed that mice
homozygous for the mutation were present at the expected frequency and, furthermore, that
these NR1 hypomorphic mice were very close in size to the wild type littermates. The NR1
mutation was maintained on the C57BL/6 and 129/SvEv genetic backgrounds by breeding
heterozygous animals. Resulting heterozygous offspring from these crosses were used to
maintain the lines and to provide heterozygous breeders for the generation of the F1 hybrid
homozygous mice (NR1 -/-) and their control populations (NR1 +/+).
Both male and female mice were used in these studies. Genders were balanced to the extent
possible among the treatments to obtain approximately equal numbers of male and female mice
in each group. The sample size available for study was not sufficient to test for gender effects
in a statistically meaningful way but no obvious gender differences were apparent in the
behavioral activation or Fos induction in response to TZG.
4.2 Drug Treatments
Mice were injected i.p with D,L-(tetrazol-5-yl)glycine (TZG) [Tocris] (dissolved in saline) at
doses of 1.25 or 1.5 mg/kg. Mice were perfused for immunocytochemistry (see below) 90
minutes after the injections. The doses were chosen from preliminary studies to be threshold
seizure-inducing. The survival period was chosen because it is near the peak of the Fos protein
expression found in previous work (Inada et al., 2007).
4.3 Immunohistochemistry
Immunocytochemical procedures were performed according to the previously published
protocols (Duncan et al., 1993; Miyamoto et al., 2004). Mice were deeply anesthetized with
chloral hydrate (400 mg/kg, i.p.) and then perfused through the left cardiac ventricle with ice-
cold 100mM sodium phosphate-buffered saline (PBS, pH=7.4) for 1 min, at a rate of 3ml/min,
followed by 4% paraformaldehyde for 3 min at the same rate of perfusion. The brains were
removed after perfusion and fixed with 4% paraformaldehyde overnight. Coronal sections (50
μm) were cut from each brain using a vibratome and placed in PBS. Sections were treated with
5% normal goat serum (Vector Laboratories, Burlingame, CA) and 0.1% Triton X-100 in PBS
for 30 min. and then were incubated for 72 hours at 4 degrees C with a Fos antibody [gift from
Dr. Peter Petruz]. After incubation with the Fos antibody, sections were incubated for 1h with
biotinylated anti-rabbit IgG (Vector Laboratories, Burlingame, CA). Sections were then
incubated with avidin-biotin complex [Vecstain Elite ABC kit; Vector Laboratories] for 1h.
Sections were then placed in a solution containing 0.05% 3,3′-diamino-benzidene
tetrahydrochloride, 0.005% cobalt chloride, 0.008% nickel ammonium sulfate, and 0.02%
hydrogen peroxide.
4.4 Quantification of Fos expression
Cells exhibiting nuclear staining for Fos in selected brain regions were counted at a
magnification of 200× by an experimenter blind to the treatment group. Four treatment groups
were evaluated: NR1 +/+ saline (n=6), NR1 +/+ TZG 1.25 mg/kg (n=16), NR1 -/- saline (n=7),
and NR1 -/- TZG 1.25 mg/kg (n=9). From preliminary studies, regions of interest were chosen
based on consistent and robust induction of Fos in response to TZG. The location of the areas
for counting within each brain region were guided by the atlas of Franklin and Paxinos (Franklin
and Paxinos, 1997). Counts were taken bilaterally in two sections per mouse for each region.
For the hippocampal sub-regions, arcuate nucleus, and nucleus of the solitary tract, cells were
counted in 50×250 μm, 100×100 μm, and 100×200 μm areas, respectively, due to the small
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size of the regions. For other regions cell counts were made in 250×500 μm fields. Since only
2 mice in each genotype survived for the 1.5 mg/kg dose, these mice were not included in the
quantitative analysis but were processed for immunocytochemistry and qualitative analysis.
4.5 Statistical Analyses
Analysis of Variance (ANOVA) was used to assess treatment effects for each brain region.
When the ANOVAs indicated a significant group effect for a brain region (p < .05), post-hoc
pair-wise comparisons were made between the individual treatment groups using Tukey’s
multiple comparison tests. For data on the proportions of NR1 +/+ and NR1 -/- mice exhibiting
seizures we performed a two-by-two factorial logistic regression analysis to examine effect of
treatment and genotype on proportion of mice that seized after the 2 doses of TZG (1.25 and
1.5 mg/kg). Because both cells in the saline condition had zero mice with seizures, including
those cells in the logistic regression was problematic computationally and those groups were
not included in the analysis.
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Counts of Fos immunoreactive cells in NR1 +/+ and NR1 -/- mice after administration TZG
(1.25 mg/kg). Data are mean ± SEM and the number of mice in each group is indicated in the
top panel. Mice were injected i.p. with TZG and perfused 90 minutes latter. Abbreviations:
CA1-P, hippocampus CA1 pyramidal cell layer; CA3-P, hippocampus CA3 pyramidal cell
layer; DG, granule cell layer of dentate gyrus; CA1-SR, CA1 stratum radiatum; BLA,
basolateral nucleus of amygdala, CeA, central nucleus of amygdala; Cing, cingulate cortex;
Pir, pyriform cortex; PV paraventricular nucleus of thalamus; LSN, lateral septal nucleus; Cpu,
caudate putamen; BN bed nucleus of stria terminalis; VHT, hypothalamus ventral medial
nucleus; ARC; hypothalamic arcuate nucleus.
* Significantly different from NR1 +/+ group, p < .05.
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Sections immunocytochemically stained for Fos from NR1 +/+ and NR1 -/- mice after injection
of TZG (1.5 mg/kg).
Duncan et al. Page 10














Sections immunocytochemically stained for Fos from NR1 +/+ and NR1 -/- mice after injection
of TZG (1.25 mg/kg). Abbreviations: Hip, hippocampus; HT, hypothalamus; Amg, amygdala.
Higher magnification of the hypothalamic region is shown in Figure 4.
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Sections immunocytochemically stained for Fos in the hypothalamus for NR1 +/+ and NR1
-/- mice after injection of saline or TZG. Abbreviations: MT, mammalothalamic tract; DM,
dorsomedial nucleus; VMH, ventromedial nucleus; Arc, arcuate nucleus.
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Sections immunocytochemically stained for Fos of the brain stem for NR1 +/+ and NR1 -/-
mice after injection of saline or TZG. Abbreviations: AP, area postrema; N Sol, nucleus of the
solitary tract; N12, motor nucleus of the 12th cranial nerve.
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Table 1
Number of mice exhibiting seizures in NR1 +/+ and NR1 -/- genotypes after injection of TZG. Numerator values are
the number of mice that exhibited tonic-clonic seizures and denominators are the total number of mice tested. Mice
that did not exhibit tonic-clonic seizures expressed no obvious form of seizure activity. All tonic-clonic seizures were
fatal within 1 minute or less after initiation
Treatment NR1 +/+ NR1 -/-
Saline 0/6 0/7
TZG 1.25 mg/kg 3/19 5/14
TZG 1.5 mg/kg 3/5 3/5
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